Formosa Pharmaceuticals Partner

Partnering and Collaboration

Business Development Activities

Formosa Pharma business development

Formosa Pharmaceuticals embraces a flexible model of partnership and is dedicated to maximizing the potential and the value of the relationship for both us and our partners.  We do so through an enthusiastic and clear strategic view, with comprehensive coverage from drug development expertise, technology, and solid value chain in manufacture and quality.

Partner for Ophthalmology Asset|APP13007-Inflammation and Pain Treatment after Cataract Surgery

Formosa Pharma Ophthalmic Drugs

We respect market differences among different territories and countries.
Flexible to work with partner in market access model.
We are seeking out-licensing partners for the US market.
For other regions and territories, we also welcome regional specialty pharmaceutical companies to discuss cooperation opportunities with us.

Strategic Partner

CGG
  • Strategic partnership for the development and commercialization of APP13007
  • Upfront payment
  • Potential milestone payments
  • Royalties on gross profit
  • Territory:Mainland China, Kong Kong and Macau, except Taiwan.
  • The number of cataract surgeries in China in 2019 reached 4.3 million cases, a rapid increase of 15% every year.

Partner for Ophthalmology Asset|APP13002-for Infectious Eye Diseases treatment

APP13002 Inquiry

APP13002 is in IND-enablement stages and is available for licensing or co-development either regionally or globally.

We welcome regional specialty pharmaceutical companies to discuss cooperation opportunities with us.

We are seeking partners who are interested in China-US dual registration.

Partner for Oncology Biosimilar Asset|TSY-0110 Biosimilar Kadcyla®

TSY-0110 Breast Cancer ADC

TSY-0110 is flexible to work with the partners’ strategy.

Co-development with partners in the scope of a Global Phase 3 study.

Leveraging in integration and manufacturing advantages to ensure successful CMC development, regulatory registration and scalability for TSY-0110.

Partner for APNT Technology| Apply APNT for Your Asset

APNT Inquiry

Collaborate with Formosa Pharmaceuticals:

  • Formosa Pharmaceuticals is open to collaborations with biopharmaceutical companies who have face challenges in formulation of APIs with poor solubility and/ or absorption.

  • Feasibility Study (conducted in 2-3 months).

  • Formosa Pharmaceuticals is flexible to work with partners in providing nanomixture or manufacture the formulation and fill-finish production to provide finished products to the partners.

Development Pipeline

Scroll to Top